Rani Therapeutics Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
RANI$0.57+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,620 | $18,618 |
| Accounts receivable, net of allowance of $82 and $0, respectively | 1,960 | 2,042 |
| Marketable securities | 41,668 | 31,091 |
| Prepaid expenses and other current assets | 1,229 | 1,570 |
| Total current assets | 48,477 | 53,321 |
| Property and equipment, net | 659 | 736 |
| Operating lease right-of-use asset | 3,147 | 4,318 |
| Other assets | 246 | 246 |
| Total assets | $52,529 | $58,621 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $454 | $309 |
| Accrued expenses and other current liabilities | 4,158 | 3,943 |
| Current portion of deferred revenue | 3,416 | 6,831 |
| Current portion of operating lease liability | 1,195 | 1,586 |
| Total current liabilities | 9,223 | 12,669 |
| Long-term deferred revenue | — | 1,708 |
| Operating lease liability, less current portion | 1,952 | 2,732 |
| Total liabilities | 11,175 | 17,109 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Class A common stock, $0.0001 par value - 800,000 shares authorized; 115,491 and 97,622 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 11 | 9 |
| Class B common stock, $0.0001 par value - 40,000 shares authorized; 23,970 and 23,970 issued and outstanding as of September 30, 2026 and December 31, 2025 | 2 | 2 |
| Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 188,750 | 165,578 |
| Accumulated other comprehensive (loss)/gain | (57) | 1 |
| Accumulated deficit | (154,733) | (132,580) |
| Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. | 33,973 | 33,010 |
| Non-controlling interest | 7,381 | 8,502 |
| Total stockholders' equity | 41,354 | 41,512 |
| Total liabilities and stockholders' equity | $52,529 | $58,621 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.